PACE-B presented by Nicholas van As Total game changer! #ASTRO23

#SBRT actually numerically better - will need more time to see whether it will be statistically superior. Between PACE-A and B, SBRT is the new SOC option for intermediate risk prostate ca (better sexual and incontinence vs RP; same efficacy, more convenient than CRT)

SBRT a new SOC option

RADICALS-RT trial was just updated at #ESMO23 by Dr. Noel Clarke. The trial compared adjuvant versus salvage RT in localized prostate cancer after radical prostatectomy. Similar benefit for MFS or OS.

Bone Met week 2/5 Post-op RT after surgical stabilization, should you treat entire hardware? YES sciencedirect.com/science/articl…

Radiation to asymptomatic bone metastases reduces SREs (incl fractures, cord compression). Primary results of our phase 2 RCT ⚖️ were published (below). If you don’t have access to the full manuscript 📑, please DM me. 🙏 #radonc #medonc

Happy to share our experience of primary ablative radiotherapy for #breastcancer in people that are not surgical candidates. Safe and effective! Lots of people to @ but special mention to Daniel Moore Palhares @hanbo_chen Dr Benazir Mirkhan Sunnybrook Health Sciences Centre Radiation Oncology authors.elsevier.com/a/1iWBu6hRQmsY…

In the #PSMA #PETimaging arm of the randomized PSMA-SRT trial UCLA and UC San Francisco, M1 disease was detected in ~10% and there was 18% more treatment escalation than in the control arm. Will this lead to improved PSA outcomes? Analysis is planned for 2025. sciencedirect.com/science/articl…

The standard of care for stage III NSCLC changes once again; Say goodbye to Durvalumab for patients with mEGFR (ex19del & L858R). #radonc astrazeneca.com/media-centre/p…

Pleased to share our secondary analysis of NRG Oncology CC001 evaluating heterogeneity of treatment effect for patients receiving HA-WBRT. doi.org/10.1093/neuonc… OncoAlert #btsm #lcsm

DOSIS - RCT in pts with painful vertebral mets Hypothesis: improved LC -> durable pain response First randomized trial with 6 mo pain reduction as prim endpoint N=63 pts randomized to SBRT vs conv. RT Significant benefit of SBRT: 69.4% vs. 41.9% (p=0.02) doi.org/10.1002/cncr.3…

🚨🚨RTOG 0848🚨🚨 Anatomically resectable PDAC randomized postoperatively 1st randomization: Gemcitabine +/- erlotinib (no benefit with erlotinib) 🔥2nd Randomization🔥 +/- Chemoradiation, 50.4 Gy/28 fx + cape ✅⬆️ DFS w/ ☢️ ✅N0, ⬆️DFS and OS (5y 48% vs 29%) w/ ☢️ #asco24

In PACE-B (Nicholas van As, #ASTRO23), only 3.5% of patients recurred after 5y. In our Sunnybrook Health Sciences Centre #SBRT series only 5% of fav int risk patients recurred after 10y (Kennedy T, #ESTRO24) Maybe you could clarify what you meant by “common occurrence”?

#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients ⁦Dr Shaun Tolan⁩ Alison Tree 💙⁩ ⁦Clive Peedell⁩ Dr. Andrew Loblaw⁩ ⁦Prof Emma Hall⁩ Prof Joe O'Sullivan⁩ authors.elsevier.com/sd/article/S03…

This is the beginning of the end for #prostatectomy in localised #prostatecancer. In future, prostatectomy should be reserved for patients with severe LUTS and large prostates. Patients deserve an honest discussion about PACE-A & Protect Trial results, & surgical learning curves

🚀groundbreaking news🎳❗️ ➡️ every PCa patient should be aware of these results before choosing the treatment 👏Nicholas van As Alison Tree 💙 Prof Emma Hall 🇬🇧 #ProstateCancer #SBRT

Well done (again) Nicholas van As and the #UKCR The Royal Marsden NHS Foundation Trust team!

SBRT superior to thermal ablation (and non invasive without tumor size limitations). This is without even accounting for use of advanced technology with adaptive RT or surface monitoring and gating, etc. Fortunate to have many excellent urologists Lee Ponsky who have helped

Wee Loon Ong leads pub in European Urology Oncology for #PATRIOT (#SBRT weekly vs every other day treatment for favourable risk #prostatecancer ) No stat diff in bioc fail (mFU of 91mo) Planning to combine with Thomas Zilli #NOVALIS study (same design) free link👉tinyurl.com/yyhd69c2

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. brnw.ch/21wTwRe